1235480-72-4

Upstream product

• 105578-34-5 acetic acid 4-chlorocarbonyl-2,6-dimethyl-phenyl ester 
• 4919-37-3 3,5-dimethyl-4-hydroxybenzoic acid 
• 23298-94-4 3,5-dimethyl-4-acetoxybenzoic acid 
• 1235480-71-3 acetic acid 2,6-dimethyl-4-(4-oxo-4H-pyrido[4,3-d][1,3]oxazin-2-yl)-phenyl ester 
• 30273-11-1 4-sec-butylaniline 

Downstream Products

• 1235480-74-6 2-{4-[2-(tert-butyldimethylsilanyloxy)ethoxy]-3,5-dimethylphenyl}-3-(4-sec-butylphenyl)-3H-pyrido[4,3-d]pyrimidin-4-one 
• 1235479-83-0 3-(4-sec-butylphenyl)-2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)pyrido[4,3-d]pyrimidin-4(3H)-one 
• 1235480-73-5 3-(4-sec-butylphenyl)-2-(4-hydroxy-3,5-dimethylphenyl)-3H-pyrido[4,3-d]pyrimidin-4-one 

Relevant academic research and scientific papers

Quinazolin-4(3H)-ones capable of upregulating the expression of endogenous apolipoprotein A-1

An application claims non-naturally occurring upregulators of apolipoprotein A-I (ApoA-l) quinazolin-4(3H)-ones. The claimed quinazolin-4(3H)-ones are efficacious in upregulating the expression of endogeneous ApoA-l, and can potentially treat and prevent

COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE

Disclosed are novel compounds that are useful for regulating the expression of apolipoprotein A-I (ApoA-l), and their use for the treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis. Also disclosed are pharmaceutical compositions comprising the novel compounds.